We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
215
Reports published
10k+
Readers in database
£25.5m placing at 56p with new & existing investors extends @RedxPharma's cash runway to end-2022; providing funds to maintain existing pipeline momentum (incl. for completion of the RXC004 Phase II programme) & to progress earlier stage assets. $REDX https://www.trinitydelta.org/companies/redx-pharma/
The €0.9m NBS prototype development deal highlights the inherent value within @NexstimOyj's #TMS platform. @SmartfocusTMS highly accurate #brain mapping has potential in #diagnostics & #therapeutics to benefit patients with brain diseases. $NXTMH / $NXTMS https://www.trinitydelta.org/companies/nexstim/
$100m investment from @CPPInvestments provides additional funds to maintain momentum as @HChiMed progresses across multiple fronts. Clinical & commercial catalysts over the next 6-18m should unlock significant upside potential. For more on $HCM visit: https://www.trinitydelta.org/companies/chi-med/
New funds of £33m transform @scancellpharma's outlook, shifting focus onto execution. Cash to end-CY23 will fund progress of broader #ImmunoBody & #Moditope portfolios, further #Avidimab / TaG antibody development, & #COVIDITY progress. For more on $SCLP: https://www.trinitydelta.org/companies/scancell/
More detail & expert insights into @MereoBioPharma's anti-#TIGIT programme #egitilimab expected at the Nov 24 $MREO / $MPH R&D day, which will also cover #alvelestat progress in #AATD & #COVID19 respiratory disease.
A positive update to the FY20 outlook from @NexstimOyj, with increased net sales & decreased operating loss expected vs FY19. $NXTMH / $NXTMS
Please sign up here to be added to our distribution database
